On GLP-1 drugs, match access with vigilance, Pg10

Key Highlights:

• Semaglutide's patent expiry in India will lead to cheaper generic GLP-1 receptor agonists.
• Approximately 50 brands may become available, potentially reducing costs by one-third to one-fifth.
• These drugs address Type-2 diabetes, promote weight loss, and lower cardiovascular risk.
• The CDSCO classifies GLP-1 medicines as Schedule H drugs, requiring a valid prescription.

Detailed Insights:

• Wider access to GLP-1 drugs benefits middle- and lower-income patients in India, which is facing diabetes and obesity epidemics.
• The availability of multiple brands could outpace regulation, leading to misuse, as these drugs have side effects and aren't for cosmetic use.
• Prescribing thresholds based on Western populations may not be suitable for India, where metabolic risks appear at lower body weights.
• Monitoring outcomes, adverse effects, and long-term use in the Indian population is crucial due to differences from original study groups.
• Tighter prescription protocols, pharmacovigilance, and eligibility criteria are needed to prevent misuse, and the CDSCO has issued advisories on advertising.

Key Concepts Involved:

• GLP-1 Receptor Agonists: Drugs that regulate Type-2 diabetes, aid weight loss, and lower cardiovascular risk.
• Pharmacovigilance: The practice of monitoring the effects of medical drugs after they have been licensed for use.
• Schedule H Drugs: Drugs for which a valid prescription is mandatory for procurement, as classified by the CDSCO.